Safety and Efficacy of Preventative COVID Vaccines: The StopCoV Study
Safety and Efficacy of Preventative COVID Vaccines: The StopCoV Study
Simple item page
Full item details
- creativework.keywords - en
- COVID-19
- vaccine
- antibody
- cohort
- elderly
- dc.contributor.author
- Walmsley, Sharon
- Szadkowski, Leah
- Wouters, Bradly
- Clare, Rosemarie
- Colwill, Karen
- Rochon, Paula
- Brudno, Michael
- Ravindran, Rizani
- Raboud, Janet
- McGeer, Allison
- Oza, Amit
- Graham, Christopher
- Silva, Amanda
- Manase, Dorin
- Parente, Laura
- Simpson, Jacqueline
- Dayam, Roaya Monica
- Pasculescu, Adrian
- Gingras, Anne-Claude
- dc.date.accessioned
- 2024-01-04T20:32:38Z
- dc.date.available
- 2024-01-04T20:32:38Z
- dc.date.issued
- 2022-02-10
- dc.description.abstract - en
- BACKGROUND: To partially immunize more persons against COVID-19 during a time of limited vaccine availability, Canadian public health officials recommended extending the vaccine dose interval and brand mixing. Impact on the antibody response among the older ambulatory population was unclear. METHODS: Decentralized prospective cohort study with self-report of adverse events and collection of dried blood spots. Data is presented for 1193 (93%) of the 911 older (aged >70 years) and 375 younger (30-50 years) recruits. FINDINGS: Local and systemic reactivity rates were high but short-lived, particularly in the younger cohort and with mRNA-1273 vaccine. After a single COVID-19 vaccine, 84% younger but only 46% older participants had positive IgG antibodies to both spike protein and receptor binding domain (RBD) antigens, increasing to 100/98% with the second dose respectively. In multivariable linear regression model, lower normalized IgG RBD antibody ratios two weeks after the second dose were statistically associated with older age, male gender, cancer diagnosis, lower body weight, BNT162b2 relative to mRNA-1273 and longer dose intervals. Antibody ratios in both cohorts declined 12 weeks post second vaccine dose. INTERPRETATION: We report success of a decentralized serology study. Antibody responses were higher in the younger than older cohort and were greater for those with at least one mRNA-1273 dose. The immunity threshold is unknown but correlations between binding and neutralizing antibodies are strongly positive. Trends with time and at breakthrough infection will inform vaccine booster strategies. FUNDING: Supported by the Public Health Agency of Canada and the University Health Network Foundation.
- dc.identifier.doi
- https://doi.org/10.1101/2022.02.09.22270734
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/1454
- dc.language.iso
- en
- dc.publisher
- medRxiv
- dc.rights - en
- Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
- dc.rights - fr
- Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
- dc.rights.openaccesslevel - en
- Green
- dc.rights.openaccesslevel - fr
- Vert
- dc.rights.uri - en
- https://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
- dc.subject - en
- Health
- dc.subject - fr
- Santé
- dc.subject.en - en
- Health
- dc.subject.fr - fr
- Santé
- dc.title - en
- Safety and Efficacy of Preventative COVID Vaccines: The StopCoV Study
- dc.type - en
- Submitted manuscript
- dc.type - fr
- Manuscrit soumis
- local.article.journaltitle
- medRxiv
- local.peerreview - en
- No
- local.peerreview - fr
- Non
Download(s)
Original bundle
1 - 1 of 1
Name: walmsley-preprint-safety-efficacy-preventative-covid-vaccines-stopcov-study.pdf
Size: 772.95 KB
Format: PDF
Collection(s)